Compound: zanamivir
SMILES: O=C(O)C=1O[C@H]([C@H](NC(=O)C)[C@H](C1)N=C(N)N)[C@H](O)[C@H](O)CO
InChIKey: ARAIBEBZBOPLMB-UFGQHTETSA-N
Synonyms: zanamivir, 139110-80-8, Relenza, GANA, 4-Guanidino-Neu5Ac2en, GG167, GG-167, GR-121167X, GR 121167X, GANA (inhibitor), DTXSID0023749, GG 167, 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid, L6O3XI777I, GR-121167, 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid, DTXCID503749, CHEBI:50663, 5-(acetylamino)-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid, 4-guanidino-2,4-dideoxy-2,3-didehydro-N-acetylneuraminic acid, (2R,3R,4S)-3-(acetylamino)-4-carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid, (2r,3r,4s)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1r,2r)-1,2,3-trihydroxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic acid, 4 Guanidino Neu5Ac2en, zanamivirum, (2R,3R,4S)-3-(acetylamino)-4-carbamimidamido-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid, (2R,3R,4S)-4-((diaminomethylidene)amino)-3-acetamido-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid, RefChem:56369, 4 Guanidino 2 Deoxy 2,3 Didehydro N Acetylneuraminic Acid, 4-guanidino-2-deoxy-2,3-didehydro-N-acetylneuraminic acid, J05AH01, Acid, 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic, 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid, 2,3-didehydro-2,4-dideoxy-4-guanidino-N-acetyl-D-neuraminic acid, 5-acetylamino-2,6-anhydro-4-guanidino-3,4,5-trideoxy-D-galacto-non-enoic acid, 5-acetylamino-4-guanidino-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid, Zanamavir, MFCD00866966, (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid, ZMR, CHEMBL222813, C12H20N4O7, 551942-41-7, ZANAMIVIR TFA, (2R,3R,4S)-3-Acetamido-4-guanidino-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid, (2R,3R,4S)-3-acetamido-4-guanidino-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid, (2R,3R,4S)-4-Guanidino-3-(prop-1-en-2-ylamino)-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid, Relenza (TN), CAS-139110-80-8, 4-Guanidino-NeueAc2en, UNII-L6O3XI777I, Dectova, Zanamivi, Zanamivir [USAN:INN:BAN], HSDB 7437, 2qwe, ARAIBEBZBOPLMB-UFGQHTETSA-N, NCGC00164561-01, 139110-80-8 (free base), GR121167X, Zanamivir (Relenza), Zanamivir (Standard), Zanamivir hydrate CRS, Zanamivir (Relenza)?, Relenza, GG 167, 1a4g, Zanamivir (USP/INN), ZANAMIVIR [INN], ZANAMIVIR [MI], Zanamivir for assay CRS, ZANAMIVIR [HSDB], ZANAMIVIR [USAN], GlyTouCan:G87167MM, ZANAMIVIR [VANDF], ZANAMIVIR [MART.], SCHEMBL9501, SCHEMBL9502, ZANAMIVIR [USP-RS], ZANAMIVIR [WHO-DD], GNA, BIDD:GT0349, BDBM4934, orb1305352, ZANAMIVIR [ORANGE BOOK], Zanamivir, >=98% (HPLC), GTPL12307, ZANAMIVIR [USP MONOGRAPH], G87167MM, MSK10031, Tox21_112190, BDBM50219992, BDBM50330326, EBC-26618, HY-13210R, s3007, AKOS015841013, AKOS015994539, Tox21_112190_1, BS-1017, CCG-267828, CS-0631, DB00558, MZ04270, NCGC00164561-02, NCGC00164561-08, NCGC00164561-11, (2R,3R,4S)-3-acetamido-4-((diaminomethylene)amino)-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid, (2R,3R,4S)-4-carbamimidamido-3-acetamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid, 5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid, HY-13210, SY102286, NS00003906, Z0023, C08095, C72554, D00902, AB01566897_01, EN300-26991905, Q146075, BRD-K23067689-001-02-1, Zanamivir Working Standard (Secondary Reference Standard), Zanamivir, United States Pharmacopeia (USP) Reference Standard, Zanamivir for assay, EuropePharmacopoeia (EP) Reference Standard, Zanamivir for system suitability, European Pharmacopoeia (EP) Reference Standard, (2R,3R,4S)-3-(ACETYLAMINO)-4-{[AMINO(IMINO)METHYL]AMINO}-2-[(1R,2R)-1,2,3-TRIHYDROXYPROPYL]-3,4-DIHYDRO-2H-PYRAN-6-CARBOXYLIC ACID, (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acidEE, (4S,5R,6R)-5-acetamido-4-(diaminomethyleneamino)-6-((1R,2R)-1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid, (4S,5R,6R)-5-acetylamino-4-guanidino-6-((1R,2R)-1,2,3-trihydroxy-propy)-5,6-dihydro-4H-pyran-2-carboxylic acid, (4S,5R,6R)-5-acetylamino-4-guanidino-6-((1R,2R)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid, (4S,5R,6R)-5-Acetylamino-4-guanidino-6-((1R,3R)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid, (4S,5R,6R)-5-Acetylamino-4-guanidino-6-((R)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid, (4S,5R,6R)-5-Acetylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid, 4-diaminomethylamino-3-methylcarboxamido-2-(1,2,3-trihydroxypropyl)-(3R)-3,4-dihydro-2H-6-pyrancarboxylic acid(Zanamivir), 5-Acetamido-2,6-anhydro-4-(carbamimidoylamino)-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid, 5-acetamido-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid, 5-Acetylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid, 5-Acetylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid(zanamivir), 5-Formylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid, D-glycero-D-galacto-Non-2-enonic acid, 5-(acetylamino)-4-(aminoiminomethyl)amino)-2,6-anhydro-3,4,5-trideoxy-
Theoretical properties:
molecular_formula: C12H20N4O7
molecular_weight: 332.31 g/mol
exact_mass: 332.13319899 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 7
hydrogen_bond_acceptor_count: 8
rotatable_bond_count: 6
heavy_atom_count: 23
topological_polar_surface_area: 201 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: White to off-white powder
color: White to off-white powder
melting_point: 256 °C
solubility: In water, 18,000 mg/L at 25 °C
Descriptions:
pubchem: Zanamivir is a member of guanidines. It has a role as an antiviral agent and an EC 3.2.1.18 (exo-alpha-sialidase) inhibitor.
chembl: ZANAMIVIR is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Zanamivir, sold under the brand name Relenza among others, is an anti-viral medication used to treat and prevent influenza caused by influenza A and influenza B viruses. It is a neuraminidase inhibitor and was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo Wellcome in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B. Zanamivir is the first neuraminidase inhibitor commercially developed. It was developed by GlaxoSmithKline.